Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis

RY Limen, R Sedono, A Sugiarto… - Expert Review of Anti …, 2022 - Taylor & Francis
Background Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …
被引用次数：37 相关文章

Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis

RY Limen, R Sedono, A Sugiarto… - Expert review of anti …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …

Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.

RY Limen, R Sedono, A Sugiarto… - Expert Review of Anti …, 2021 - europepmc.org
Background Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …

Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis

RY Limen, R Sedono, A Sugiarto… - Expert Review of Anti …, 2021 - scholar.ui.ac.id
Background: Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …
[HTML] nih.gov

[HTML][HTML] Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis

RY Limen, R Sedono, A Sugiarto… - Expert Review of Anti …, 2021 - ncbi.nlm.nih.gov
Background Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …